Page 144 - CW E-Magazine (4-6-2024)

Pharmaceuticals

GEARED FOR GROWTH
Sun Pharma opens new plant in Bangladesh

Sun Pharmaceuticals (EZ) Ltd.,
a subsidiary of Sun Pharmaceutical
Industries Ltd., has opened a new manu-
facturing plant at Meghna Industrial
Economic Zone in Narayanganj, Bang-
ladesh.

Private Industry and Investment
Adviser of Bangladesh Prime Mini-
ster Mr. Salman Rahman and Indian
High Commissioner to Bangladesh
Mr. Pranay Verma jointly inaugurated
the new plant. This is the company’s
second investment in Bangladesh with
a production capacity of over 1-billion
tablets and capsules per year.

Speaking at the ceremony, the High
Commissioner Verma highlighted the
new investment as part of the growing growth story of Bangladesh’s pharma- nomic Zone of Bangladesh, is not just
economic and industrial engagement ceutical industry, meeting about 30 a testament to India’s continued com-
between Bangladesh and India, and a percent of the Active Pharmaceutical mitment to promote partnership with
visible symbol of the recent transforma- Ingredients (API) demand of Bangladesh. Bangladesh, but also refl ects the grow-
tion of their relationship. He noted that He stressed that the plant, which is the ing interest among Indian businesses
India has been a credible partner in the fi rst pharmaceutical unit in any Eco- to invest in Bangladesh.

EXPANDING PRESENCE
JB Pharma supplies lozenges in Europe through

two partnerships, looks at US next

JB Pharma has, for the fi rst time, Lozenges account for 80% of JB Mexico and Brazil would be looked
supplied lozenges in Europe through Pharma’s contract development and at in 2025/26, he added.
partnerships with Kenvue (formerly manufacturing (CDM) business. The
J&J’s consumer healthcare division) business clocked $50-mn revenues, and Over three years ago, JB Chemicals &
and Krka, informed Mr. Nikhil Chopra, are in the immunity space (zinc/vitamin Pharmaceuticals’ promoter family sold
JB Pharma Chief Executive Offi cer and C and menthol) for Kenvue and cough its controlling stake in the company to
Whole-time Director. for Krka. KKR. The company has since recast
itself and will stay focussed in the present
The company expects to supply loz- The present year will see more geo- year on key segments including chronic
enges in the US by September/October, graphies and partners being added, he therapies, probiotics, paediatrics and
through its partnership with a multi- said, including melatonin lozenges hypertension, he said. The next few
national consumer health company, (for sleep issues) that would be sup- months would also see new products in
he said in an interview with the Hindu plied to the Middle East and South East ophthalmology from their layered deal
Businessline. Asia, later this year. Markets including with Novartis.

144 Chemical Weekly June 4, 2024

Contents Index to Advertisers Index to Products Advertised